Eli Lilly reported on Thursday Second quarter results and revenue exceeded all expectations, raising full-year revenue guidance by $3 billion as sales of the hit diabetes drug Mounjaro and weight-loss injection Zepbound soared.

Eli Lilly shares rose greater than 10% in early trading Thursday.

The pharmaceutical manufacturer now expects sales of between $45.4 billion and $46.6 billion for the approaching 12 months, a rise of $3 billion at each end of the range.

The company also raised its adjusted annual earnings to $16.10 to $16.60, in comparison with a previous forecast of $13.50 to $14 per share.

Eli Lilly said the rise in guidance was primarily as a result of strong performance from Mounjaro and Zepbound and partly as a result of “improved clarity” regarding the corporate's manufacturing expansions and planned launch of Mounjaro outside the U.S. The company said it achieved several supply-related milestones in the course of the quarter, but didn’t provide specific details.

Demand far exceeds supply for incretin drugs like Zepbound and Mounjaro. These drugs mimic hormones produced within the gut to suppress appetite and regulate blood sugar. This has forced Eli Lilly and its rival Novo Nordisk to speculate massively to spice up production.

But Eli Lilly's supply shortages may steadily ease. On Friday, the drug database of the American Food and Drug Administration (FDA) reported that after an extended period of shortages, all doses of Zepbound and Mounjaro were available again within the USA.

However, the corporate cautioned that the expected increase in demand for certain doses of its incretin drugs may lead to temporary “supply shortages.”

“We're just seeing incredible demand and we're not even trying to promote this drug particularly heavily,” Eli Lilly CEO David Ricks said in an interview with CNBC. “What you're seeing here is just organic consumer demand as we've shipped more product and brought more supply online in the United States.”

Ricks said the corporate has built six manufacturing plants, a few of that are already in operation, and hired hundreds of employees to extend production. Eli Lilly expects production of incretin drugs to be 50% higher within the second half of 2024 than in the identical period last 12 months, he noted.

“We're on track to do that until 2025,” he said. Ricks added that Eli Lilly remains to be developing more convenient weight-loss pills that might help the corporate meet rapidly increasing demand.

Here's what Eli Lilly reported for the second quarter and what Wall Street expected based on an analyst survey conducted by LSEG:

• Earnings per share: USD 3.92 adjusted versus USD 2.60 expected
• Revenue: 11.30 billion US dollars in comparison with expected 9.92 billion US dollars

The pharmaceutical giant posted net profit of $2.97 billion, or $3.28 per share, for the second quarter. In the identical period last 12 months, profit was $1.76 billion, or $1.95 per share.

Excluding one-time items related to the worth of intangible assets and other adjustments, Eli Lilly reported earnings of $3.92 per share for the second quarter of 2024.

The company reported second-quarter revenue of $11.30 billion, up 36% from the identical period last 12 months.

According to Eli Lilly, sales were primarily as a result of increased demand for Mounjaro and Zepbound as production increases improved supply within the United States.

It is Zepbound's second full quarter within the U.S. market after receiving regulatory approval in November. The weekly money injection brought in revenue of $1.24 billion for the period, well above the $922.2 million expected by analysts, in keeping with StreetAccount.

Meanwhile, Mounjaro posted second-quarter revenue of $3.09 billion, greater than triple the revenue of the identical period last 12 months. Analysts had expected revenue of $2.39 billion, in keeping with StreetAccount.

Prices for Mounjaro were higher within the U.S. within the second quarter, partly as a result of increased access to the drug and lower use of savings card programs in comparison with the identical period last 12 months.

However, the corporate said savings cards are expected to have “only a minimal effect” on actual price comparisons within the second half of the 12 months since the $25 monthly coupon for patients without insurance coverage for Mounjaro expired in June.

Ricks said prices for Eli Lilly's incretin drugs were “fairly stable” within the second quarter.

The situation is different for Novo Nordisk, which on Wednesday reported weaker-than-expected second-quarter sales of its weight-loss drug Wegovy and the diabetes injection Ozempic, partly as a result of price pressure.

Wegovy's revenue was hit by higher-than-expected price concessions to U.S. pharmacy profit managers, who negotiate drug discounts with manufacturers on behalf of insurers, Novo Nordisk executives said Wednesday during a quarterly earnings conference call.

Eli Lilly shares have risen greater than 30% this 12 months after rising nearly 60% in 2023, because of rising demand for the corporate's weight-loss and diabetes drugs — and increased investor interest of their potential as treatments for other health conditions. That popularity comes despite their high monthly prices, inconsistent insurance coverage and intermittent supply shortages.

With a market capitalization of over $730 billion, Eli Lilly is the biggest pharmaceutical company based within the United States

LOS ANGELES — In the primary direct comparison of two blockbuster drugs under real-world conditions, individuals who Mounjaro lost significantly more weight than their colleagues who Ozempic – and the longer patients took the medication, the larger this gap became.

After three months of weekly injections, patients taking Ozempic lost a mean of three.6 percent of their body weight, while the typical weight reduction for patients taking Mounjaro was 5.9 percent.

After six months, Ozempic patients had lost a mean of 5.8% of their weight, while the typical weight reduction for Mounjaro patients was 10.1%.

And after a full yr, those taking Ozempic had lost a mean of 8.3% of their weight, while those taking Mounjaro had lost a mean of 15.3%.

The researchers who conducted the evaluation also found that in comparison with people taking Ozempic, people taking Mounjaro were 2.5 times more more likely to lose a minimum of 10% of their baseline weight through the first yr of taking the medication, and people taking Mounjaro were greater than 3 times more more likely to lose a minimum of 15% of their weight.

The results were published Monday in JAMA Internal Medicine.

Dr Matthew FreebyEndocrinologist and director of the Gonda Diabetes Center of UCLA's Geffen School of Medicine, said the study results were consistent with observations he had made in his own patients.

“From the perspective of weight loss and lowering blood sugar levels in type 2 diabetics, we see stronger effects with Mounjaro than with Ozempic,” said Freeby, who was not involved within the research.

Both drugs were approved by the US Food and Drug Administration to assist individuals with diabetes to maintain their blood sugar under control. By mimicking a hormone called Glucagon-like peptide 1or GLP-1, they increase the body’s own production of insulindecelerate digestion, increase the sensation of satiety and reduce appetite.

Mounjaro also mimics a related hormone called glucose-dependent insulinotropic peptideor GIP.

When the drugs were tested against placebos in clinical trials, each helped patients lose significant weight. Tirzepatidethe lively ingredient in Mounjaro, seemed simpler than Semaglutidethe lively ingredient in Ozempic. However, the studies weren’t conducted under the identical conditions, so the outcomes are usually not directly comparable.

Researchers from Truvetaa healthcare data and analytics company owned by 30 health systemstried to vary this by examining their electronic health records. The work also gave them the chance to see how the patients fared outside the idealized context of a clinical trial, which usually provides free medication, regular check-ups, and other kinds of support.

Using their database, the researchers were in a position to discover individuals who filled their first prescription for either drug between May 2022, the month Mounjaro joined Ozempic. Obtaining FDA approval — and September 2023. Patients didn’t need to have type 2 diabetes to take part in the study, but that they had to be chubby (with a Body mass index of a minimum of 27) or obese (with a BMI of a minimum of 30).

The Truveta team found about 41,000 people in over 30 states who met all the factors for inclusion within the study. Because Ozempic patients outnumbered Mounjaro patients by 3 times, researchers used information on age, race, income, health history and other aspects to create a gaggle of Ozempic patients that almost all closely matched Mounjaro patients. The result was a population of nearly 18,400 people evenly split between the 2 drugs.

Before the primary dose of medication, the typical weight of individuals in each groups was 243 kilos. But it didn't take long for the 2 groups to differ from one another.

After accounting for unmeasured influences that might have confounded the outcomes, the Truveta team found that weight reduction was 2.4 percentage points higher in Mounjaro patients than in Ozempic patients after three months, 4.3 percentage points after six months, and 6.9 percentage points after one yr.

Mounjaro also outperformed Ozempic when it comes to patients' success in reaching various milestones inside a yr of beginning to take either drug.

Nearly 82% of Mounjaro patients lost a minimum of 5% of their body weight, in comparison with 67% of patients taking Ozempic. Similarly, 62% of Mounjaro patients and 37% of Ozempic patients lost a minimum of 10% of their baseline weight, while 42% of Mounjaro patients and 18% of Ozempic patients lost a minimum of 15% of their baseline weight.

The researchers didn’t investigate the biological mechanisms of the 2 drugs, but study leaders Tricia Rodrigueza senior applied scientist at Truveta Research, said Mounjaro could also be simpler because it really works in two ways moderately than simply one.

The large difference in effectiveness was not accompanied by a measurable difference in the speed of moderate or severe negative effects reminiscent of intestinal obstruction and pancreatitis, which were rare in patients in each groups. The researchers didn’t compare the chance of milder problems reminiscent of nausea and vomiting because people wouldn’t necessarily report these to their doctor, Rodriguez said.

Regardless of which drug they took, patients with type 2 diabetes lost less weight than patients without the disease, the researchers found. This may very well be explained by the incontrovertible fact that certain diabetes treatments could cause weight gain and that some patients eat more throughout the day to maintain their blood sugar levels low. change into too lowsaid Freeby.

It can be possible that folks who sought prescriptions for Ozempic or Mounjaro with the goal of shedding weight were more motivated to proceed taking the drug, even when it was expensive or caused unpleasant negative effects, or that they were more more likely to adopt other behaviors that promote weight reduction, Rodriguez said.

Finding this out is “a crucial topic for future research,” she said.

People currently taking Ozempic probably have a more pressing query on their minds: Should I switch to Mounjaro?

Nick Stuckyan infectious disease physician at Providence Portland Medical Center and lead creator of the study, said the outcomes alone shouldn’t prompt patients to stop taking a drug that works for them. The risk of negative effects, insurance coverage and availability of the drug also must be considered.

“Although tirzepatide was significantly more effective than semaglutide, patients taking both drugs experienced significant weight loss,” said Stucky, who can be vice chairman of research at Truveta.

Freeby agreed with this opinion.

“If someone is doing well with a drug, why make trouble?” he said.

Freeby added that Ozempic (and its sister drug wayswhich is approved by the FDA specifically for weight reduction) has a minimum of one advantage over Mounjaro (and Zepboundits counterpart for weight reduction): In clinical studies, Ozempic has been shown to cut back the chance of heart attacks, strokes and other Cardiovascular problems in addition to Kidney failure.

“At this point, we don’t have a lot of data on Mounjaro when it comes to secondary outcomes,” he said.

___

©2024 Los Angeles Times. Visit www.latimes.com. Distributed by Tribune Content Agency, LLC.

Consumer goods for airlines

Increasing competition in weight reduction drugs